MA33734B1 - N1-pyrazolospirocétone inhibitrices d'acétyl-coa carboxylase - Google Patents

N1-pyrazolospirocétone inhibitrices d'acétyl-coa carboxylase

Info

Publication number
MA33734B1
MA33734B1 MA34850A MA34850A MA33734B1 MA 33734 B1 MA33734 B1 MA 33734B1 MA 34850 A MA34850 A MA 34850A MA 34850 A MA34850 A MA 34850A MA 33734 B1 MA33734 B1 MA 33734B1
Authority
MA
Morocco
Prior art keywords
acetyl
coa carboxylase
pyrazolospirocetone
carboxylase inhibitors
inhibitors
Prior art date
Application number
MA34850A
Other languages
Arabic (ar)
English (en)
Inventor
Daniel Wei-Shung Kung
Scott William Bagley
David Andrew Griffith
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA33734B1 publication Critical patent/MA33734B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un composé de formule (i) ou un sel pharmaceutiquement acceptable du composé, dans lequel r1, r2, r3 et r4 sont tels que présentement décrits; des compositions pharmaceutiques de celui-ci; et l'utilisation de celui-ci dans le traitement de maladies, affections ou troubles modulés par l'inhibition d'une ou des enzyme(s) acétyl-coa carboxylase(s) chez un animal.
MA34850A 2009-11-10 2012-05-10 N1-pyrazolospirocétone inhibitrices d'acétyl-coa carboxylase MA33734B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25982309P 2009-11-10 2009-11-10
PCT/IB2010/054908 WO2011058474A1 (fr) 2009-11-10 2010-10-29 Inhibiteurs de n1-pyrazolospirocétone acétyl-coa carboxylase

Publications (1)

Publication Number Publication Date
MA33734B1 true MA33734B1 (fr) 2012-11-01

Family

ID=43357094

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34850A MA33734B1 (fr) 2009-11-10 2012-05-10 N1-pyrazolospirocétone inhibitrices d'acétyl-coa carboxylase

Country Status (39)

Country Link
US (4) US8288405B2 (fr)
EP (3) EP2947082A1 (fr)
JP (1) JP5114610B1 (fr)
KR (2) KR101550557B1 (fr)
CN (1) CN102695708B (fr)
AP (1) AP3283A (fr)
AR (1) AR078944A1 (fr)
AU (1) AU2010317501B2 (fr)
BR (1) BR112012011072A2 (fr)
CA (1) CA2778886C (fr)
CL (1) CL2012000999A1 (fr)
CO (1) CO6541569A2 (fr)
CR (1) CR20120190A (fr)
CU (1) CU24077B1 (fr)
DK (1) DK2499139T3 (fr)
DO (1) DOP2012000128A (fr)
EA (1) EA020153B1 (fr)
EC (1) ECSP12011880A (fr)
ES (1) ES2444543T3 (fr)
GE (1) GEP20146169B (fr)
HN (1) HN2012000973A (fr)
HR (1) HRP20140025T1 (fr)
IL (1) IL219373A (fr)
MA (1) MA33734B1 (fr)
MX (1) MX2012005429A (fr)
NI (1) NI201200089A (fr)
NZ (1) NZ599815A (fr)
PE (1) PE20121469A1 (fr)
PH (1) PH12012500903A1 (fr)
PL (1) PL2499139T3 (fr)
PT (1) PT2499139E (fr)
RS (1) RS53156B (fr)
SI (1) SI2499139T1 (fr)
TN (1) TN2012000192A1 (fr)
TW (1) TWI394756B (fr)
UA (1) UA102336C2 (fr)
UY (1) UY33020A (fr)
WO (1) WO2011058474A1 (fr)
ZA (1) ZA201204231B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009144554A1 (fr) 2008-05-28 2009-12-03 Pfizer, Inc. Inhibiteurs de la pyrazolospirocétone acétl-coa carboxylase
CN104945420A (zh) 2009-06-29 2015-09-30 因塞特公司 作为pi3k抑制剂的嘧啶酮类
WO2011058474A1 (fr) 2009-11-10 2011-05-19 Pfizer Inc. Inhibiteurs de n1-pyrazolospirocétone acétyl-coa carboxylase
WO2011075643A1 (fr) 2009-12-18 2011-06-23 Incyte Corporation Dérivés condensés d'hétéroaryles substitués à titre d'inhibiteurs de pi3k
EP2345643A1 (fr) * 2009-12-29 2011-07-20 Polichem S.A. Nouveaux dérivés de 8-hydroxyquinoline-7-carboxamide et leurs utilisations
AR081823A1 (es) 2010-04-14 2012-10-24 Incyte Corp DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
HRP20161178T1 (hr) * 2010-09-30 2016-11-04 Pfizer Inc. N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE
BR112013010310A2 (pt) 2010-10-29 2016-11-29 Pfizer inibidores de acetil-coa carboxilase de lactama n1/n2
EP2655374B1 (fr) 2010-12-20 2019-10-23 Incyte Holdings Corporation N-(1-(phényl substitué)éthyl)-9h-purin-6-amines en tant qu'inhibiteurs de pi3k
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (fr) 2011-03-25 2012-10-04 Incyte Corporation Dérivés de pyrimidine-4,6-diamine en tant qu'inhibiteurs de pi3k
MY162167A (en) * 2011-04-22 2017-05-31 Pfizer Substituted acetyl-coa carboxylase inhibitors
KR102507287B1 (ko) 2011-09-02 2023-03-07 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
WO2014134391A1 (fr) 2013-02-28 2014-09-04 Bristol-Myers Squibb Company Dérivés de phénylpyrazole en tant que puissants inhibiteurs de rock1 et rock2
ES2731773T3 (es) 2013-03-14 2019-11-19 Celgene Quanticel Res Inc Inhibidores de la histona desmetilasa
HK1217448A1 (zh) 2013-09-12 2017-01-13 辉瑞大药厂 乙酰辅酶a羧化酶抑制剂用於治疗寻常痤疮的用途
EP3670496A3 (fr) 2013-10-17 2020-09-30 Shionogi&Co., Ltd. Inhibiteurs de acc2
WO2015191677A1 (fr) 2014-06-11 2015-12-17 Incyte Corporation Dérivés d'hétéroarylaminoalkylphényle bicycliques à titre d'inhibiteurs de pi3k
US9896436B2 (en) 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
BR112017005128A2 (pt) 2014-09-16 2018-07-31 Celgene Quanticel Res Inc inibidores de histona desmetilase
MX2017003463A (es) * 2014-09-17 2017-07-13 Celgene Quanticel Res Inc Inhibidores de histona desmetilasa.
CN107002262B (zh) 2014-11-10 2019-10-29 国立大学法人横浜国立大学 氧气发生用阳极
SI3831833T1 (sl) 2015-02-27 2023-03-31 Incyte Holdings Corporation Postopki za pripravo inhibitorja PI3K
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
US11541046B2 (en) 2017-06-30 2023-01-03 Quixgen, Inc. Spirolactone compounds
FI3713942T3 (fi) 2017-11-21 2023-05-04 Pfizer 4-(4-(1-isopropyyli-7-okso-1,4,6,7-tetrahydrospiro[indatsoli-5,4'-piperidiini]-1'-karbonyyli)-6-metoksipyridin-2-yyli)bentsoehapon kiteinen 2-amino-2-(hydroksimetyyli)propaani-1,3-diolisuola
US11465991B2 (en) 2018-03-15 2022-10-11 Yale University Pyrazole-containing macrophage migration inhibitory factor inhibitors
CA3101323A1 (fr) 2018-06-01 2019-12-05 Incyte Corporation Schema posologique destine au traitement de troubles lies a la pi3k
US12521375B2 (en) 2020-05-21 2026-01-13 Shionogi & Co., Ltd. Pharmaceutical composition for treating fatty liver disease
US10989621B1 (en) 2020-08-20 2021-04-27 Trinity Bay Equipment Holdings, LLC Online pipe integrity testing system and method
CN112028834B (zh) * 2020-09-11 2022-03-29 济南悟通生物科技有限公司 一种阿贝西利的中间体的合成方法
EP4434520A4 (fr) 2021-11-19 2025-10-29 Shionogi & Co Produit pharmaceutique pour le traitement d'une maladie cardiaque ou d'une maladie du muscle squelettique
CN115124542A (zh) * 2022-07-08 2022-09-30 河南师范大学 羟基苯取代吡唑酮并吲唑[螺]吡唑酮类化合物的合成方法
AU2023316863A1 (en) * 2022-07-29 2025-02-13 Pfizer Inc. Novel acc inhibitors
WO2025133948A1 (fr) * 2023-12-21 2025-06-26 Pfizer Inc. Inhibiteurs de l'acétyl coa-carboxylase (acc)

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US984083A (en) 1910-03-28 1911-02-14 William J Faber Floor-plane.
ATE364374T1 (de) 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
IL157253A0 (en) 2001-02-28 2004-02-19 Merck & Co Inc Acylated piperidine derivatives as melanocortin-4 receptor agonists
NZ534582A (en) 2002-02-27 2006-03-31 Pfizer Prod Inc ACC inhibitors
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
JPWO2004092179A1 (ja) 2003-04-14 2006-07-06 日本曹達株式会社 スピロ誘導体、製造法および抗酸化薬
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
WO2005113069A2 (fr) 2004-05-14 2005-12-01 Research Development Foundation Utilisation de curcumine et d'analogues de curcumine comme inhibiteurs de l'acc2
UA84208C2 (en) 2004-05-25 2008-09-25 Пфайзер Продактс Инк. Tetraazabenzo(e)azulene derivatives and analogs thereof
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
MX2008000966A (es) 2005-07-19 2008-03-26 Merck & Co Inc Nuevos derivados de espirocromanona.
US20100160255A1 (en) * 2005-07-29 2010-06-24 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
DE102006016566B4 (de) * 2005-09-22 2008-06-12 Beru Ag Zusammengesetzter Leiter, insbesondere für Glühkerzen für Dieselmotoren
ATE493412T1 (de) 2005-11-18 2011-01-15 Merck Sharp & Dohme Spirohydantoin-aryl-cgrp-rezeptorantagonisten
CN101384568B (zh) 2006-02-15 2012-12-12 雅培制药有限公司 乙酰辅酶a羧化酶(acc)抑制剂及其在糖尿病、肥胖症和代谢综合征中的应用
EA200900613A1 (ru) * 2006-11-29 2009-10-30 Пфайзер Продактс Инк. Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
PE20081559A1 (es) * 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
EP2123652A1 (fr) * 2007-02-20 2009-11-25 Takeda Pharmaceutical Company Limited Composé hétérocyclique
EP2195321B1 (fr) * 2007-04-12 2016-10-19 Pfizer Inc. Derives de 3-amido-pyrrolo[3,4-c]pyrazole-5(1h,4h,6h) carbaldehyde comme inhibiteurs de proteine kinase c
WO2009014455A1 (fr) * 2007-07-20 2009-01-29 Mark Jonathon Brownlee Système de prévision du temps de réponse à un courrier électronique
US7981904B2 (en) * 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
WO2009144554A1 (fr) * 2008-05-28 2009-12-03 Pfizer, Inc. Inhibiteurs de la pyrazolospirocétone acétl-coa carboxylase
US20110009443A1 (en) * 2008-05-28 2011-01-13 Kevin Daniel Freeman-Cook Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors
CA2729412A1 (fr) 2008-07-04 2010-01-07 Banyu Pharmaceutical Co., Ltd. Nouveaux acides spirochromanone carboxyliques
US8110570B2 (en) * 2008-07-14 2012-02-07 Cropsolution, Inc. Modulators of acetyl-coenzyme A carboxylase and methods of use thereof
WO2010044981A2 (fr) * 2008-09-18 2010-04-22 Auspex Pharmaceutical ,Inc. Inhibiteurs benzoquinoline du transporteur de monoamines vésiculaire 2
WO2011058474A1 (fr) * 2009-11-10 2011-05-19 Pfizer Inc. Inhibiteurs de n1-pyrazolospirocétone acétyl-coa carboxylase
EP2499140A1 (fr) 2009-11-10 2012-09-19 Pfizer Inc. Inhibiteurs de n2-pyrazolospirocétone acétyl-coa carboxylase
HRP20161178T1 (hr) 2010-09-30 2016-11-04 Pfizer Inc. N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE
MY162167A (en) * 2011-04-22 2017-05-31 Pfizer Substituted acetyl-coa carboxylase inhibitors

Also Published As

Publication number Publication date
CO6541569A2 (es) 2012-10-16
GEP20146169B (en) 2014-09-25
HN2012000973A (es) 2015-03-02
CU24077B1 (es) 2015-03-30
DOP2012000128A (es) 2012-08-31
JP5114610B1 (ja) 2013-01-09
HK1173724A1 (en) 2013-05-24
CR20120190A (es) 2012-05-24
BR112012011072A2 (pt) 2017-06-20
UA102336C2 (uk) 2013-06-25
US8288405B2 (en) 2012-10-16
EP2676958A1 (fr) 2013-12-25
MX2012005429A (es) 2012-06-19
KR101478517B1 (ko) 2015-01-02
TW201127838A (en) 2011-08-16
IL219373A0 (en) 2012-06-28
TWI394756B (zh) 2013-05-01
AP2012006269A0 (en) 2012-06-30
EP2499139A1 (fr) 2012-09-19
EA201290191A1 (ru) 2012-12-28
HRP20140025T1 (hr) 2014-02-14
US20130296319A1 (en) 2013-11-07
DK2499139T3 (da) 2014-01-27
EP2499139B1 (fr) 2013-12-11
PE20121469A1 (es) 2012-11-01
AU2010317501A1 (en) 2012-05-17
ECSP12011880A (es) 2012-07-31
CU20120071A7 (es) 2013-05-31
IL219373A (en) 2014-04-30
US20140288111A1 (en) 2014-09-25
US8507681B2 (en) 2013-08-13
KR101550557B1 (ko) 2015-09-04
SI2499139T1 (sl) 2014-01-31
US20110111046A1 (en) 2011-05-12
US20130030181A1 (en) 2013-01-31
CA2778886C (fr) 2014-01-07
CN102695708A (zh) 2012-09-26
RS53156B (sr) 2014-06-30
AP3283A (en) 2015-05-31
EA020153B1 (ru) 2014-09-30
EP2947082A1 (fr) 2015-11-25
AU2010317501B2 (en) 2013-06-06
KR20120099460A (ko) 2012-09-10
CA2778886A1 (fr) 2011-05-19
ZA201204231B (en) 2013-02-27
EP2676958B1 (fr) 2015-07-01
ES2444543T3 (es) 2014-02-25
WO2011058474A8 (fr) 2012-04-26
NZ599815A (en) 2013-04-26
PT2499139E (pt) 2014-02-10
PL2499139T3 (pl) 2014-04-30
NI201200089A (es) 2012-08-20
US9139587B2 (en) 2015-09-22
US8802690B2 (en) 2014-08-12
WO2011058474A1 (fr) 2011-05-19
JP2013510192A (ja) 2013-03-21
TN2012000192A1 (fr) 2013-12-12
UY33020A (es) 2011-06-30
AR078944A1 (es) 2011-12-14
KR20140034919A (ko) 2014-03-20
CN102695708B (zh) 2014-10-15
PH12012500903A1 (en) 2014-09-24
CL2012000999A1 (es) 2012-07-20

Similar Documents

Publication Publication Date Title
MA33734B1 (fr) N1-pyrazolospirocétone inhibitrices d'acétyl-coa carboxylase
MA35061B1 (fr) Dérivés de pyrazolospirocétone pour une utilisation comme inhibiteurs d'acétyl-coa carboxylase
MA42295B1 (fr) Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation
MX2013004733A (es) Inhibidores de n1/n2-lactama acetil-coa carboxilasa.
WO2019035863A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques
UA103272C2 (uk) 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
EA200801826A1 (ru) Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA32903B1 (fr) Inhibiteurs de proteine-kinases
MA37891B1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
WO2007095050A3 (fr) N-hydroxyguanidines comme modulateurs de l'indolamine 2,3-dioxygénase
EA201000098A1 (ru) Производные хиназолинамида
BR112014006763A2 (pt) n-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexa-hidro-ciclopenta[e][1,3]oxazin-4-il)-fenil)-amidas como inibidores de bace1
MA38810A1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
EA200700909A1 (ru) Азаиндолкарбоксамиды
MA33618B1 (fr) Agent thérapeutique destiné aux troubles de l'humeur
EA201000362A1 (ru) Производные 1,3-дигидроизоиндола
MA33760B1 (fr) Dérivés spirolactames et leurs utilisations
MA37691B1 (fr) 5-amino[1,4]thiazines comme inhibiteurs de bace1
MA37763B1 (fr) Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1
MA46342A (fr) Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation